



Prof. Dr. Dr. h. c. Stefan H.E. Kaufmann

Max Planck Institute for Infection Biology, Berlin, Germany

Stefan H.E. Kaufmann is interested in the immune response to intracellular bacterial infections with the emphasis on tuberculosis. He has published more than 600 articles and is a highly cited researcher. His vaccine against tuberculosis, a recombinant BCG, is currently in a phase 2 trial in infants in South Africa. Aside from this, he is highly interested in biosignatures which can be used as correlates of protection against tuberculosis. His basic research focuses on the role of innate and acquired immunity harnessing experimental animal and clinical studies as well as computational biology. He is a member of EMBO and past President of the German Society for Immunology, the European Federation of Immunological Societies and the International Union of Immunological Societies.